Valuation: Orion Oyj

Market Cap 1.15TCr 1.32TCr 1.08TCr 983.9Cr 1.84TCr 1,26400Cr 1.85TCr 13TCr 5.01TCr 64TCr 4.95TCr 4.84TCr 2,06500Cr P/E 2026 *
20.3x
P/E 2027 * 17.2x
Enterprise Value 1.14TCr 1.31TCr 1.07TCr 976.21Cr 1.83TCr 1,25400Cr 1.83TCr 13TCr 4.97TCr 64TCr 4.91TCr 4.8TCr 2,04900Cr EV / Sales 2026 *
5.43x
EV / Sales 2027 * 4.69x
Free-Float
90.5%
Yield 2026 *
2.39%
Yield 2027 * 2.66%
1 week 63.4
Extreme 63.4
63.4
1 month 63.4
Extreme 63.4
63.4
3 years 52.69
Extreme 52.69
63.55
5 years 36
Extreme 36
63.55
10 years 24.85
Extreme 24.85
63.55
Manager TitleAgeSince
Chief Executive Officer 59 01/11/2022
Director of Finance/CFO 50 01/05/2024
Chief Operating Officer 46 01/01/2022
Director TitleAgeSince
Director/Board Member 63 22/03/2017
Director/Board Member 65 22/03/2017
Director/Board Member 66 06/05/2020
Change 5-day change 1-year change 3-year change Capi.($)
0.00%0.00%0.00%+18.50% 1.32TCr
+0.04%+3.34%+53.32%+100.52% 1,02800Cr
-0.09%+1.66%+53.24%+66.45% 65TCr
-0.02%+2.66%+18.65%+71.97% 47TCr
-1.22%+3.66%+34.59%+38.81% 35TCr
-0.79%+2.73%+17.73%+25.11% 27TCr
+0.58%+6.76%+10.58%+17.75% 26TCr
+1.55%+2.20%+35.12%+45.91% 21TCr
+0.79%+1.84%-27.55%-56.48% 19TCr
-0.52%+4.45%+31.57%+98.11% 19TCr
Average +0.04%+3.26%+22.72%+42.67% 40.02TCr
Weighted average by Cap. -0.04%+3.09%+34.72%+61.44%

Financials

2026 *2027 *
Net sales 209.78Cr 240.8Cr 198.02Cr 179.83Cr 336.67Cr 23TCr 337.97Cr 2.37TCr 915.06Cr 12TCr 904.59Cr 884.33Cr 38TCr 237.37Cr 272.47Cr 224.06Cr 203.49Cr 380.94Cr 26TCr 382.42Cr 2.68TCr 1.04TCr 13TCr 1.02TCr 1TCr 43TCr
Net income 57Cr 65Cr 53Cr 49Cr 91Cr 6.23TCr 91Cr 638.79Cr 246.85Cr 3.17TCr 244.02Cr 238.56Cr 10TCr 67Cr 77Cr 63Cr 57Cr 107.19Cr 7.36TCr 107.61Cr 753.96Cr 291.35Cr 3.74TCr 288.02Cr 281.57Cr 12TCr
Net Debt -8.98Cr -10Cr -8.47Cr -7.69Cr -14Cr -988.42Cr -14Cr -101.32Cr -39Cr -502.68Cr -39Cr -38Cr -1.62TCr -33Cr -38Cr -31Cr -29Cr -53Cr -3.67TCr -54Cr -375.85Cr -145.24Cr -1.86TCr -143.58Cr -140.36Cr -5.99TCr
Logo Orion Oyj
Orion Oyj is Finland's leading pharmaceutical group. Net sales break down by family products and services as follows: - innovative medicines (43%): for the treatment of cancer and pain management; - generic, OTC and biosimilar drugs (29.3%); - branded prescription products (16.6%): notably intended for treating dysfunctions of the nervous system, cardiovascular diseases, hormonal and urological treatments; - veterinary products (7.5%); - pharmaceutical ingredients and outsourcing services (3.6%). Net sales break down primarily by source of revenue between sales of products (67.2%) and royalties (23.1%). Net sales are distributed geographically as follows: Finland (19.3%), Scandinavia (10%), Europe (28.1%), North America (25.5%) and other (17.1%).
Employees
-
Date Price Change
18/26/18 €63.40 0.00%
17/26/17 €63.40 0.00%
16/26/16 €63.40 0.00%
15/26/15 €63.40 0.00%
14/26/14 €63.40 0.00%
Trader
Investor
Global
Quality
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
6
Last Close Price
81.50EUR
Average target price
76.67EUR
Spread / Average Target
-5.93%

Quarterly revenue - Rate of surprise

-40%: Exceptional extension
d
:
:
SEIZE THE OFFER!